Bausch Health Companies Inc. develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology.
Bausch Health Companies stock last closed at $8.22, down 2.03% from the previous day, and has increased 14.97% in one year. It has overperformed other stocks in the Drug Manufacturers - Specialty & Generic industry by 0.29 percentage points. Bausch Health Companies stock is currently +47.58% from its 52-week low of $5.57, and -19.65% from its 52-week high of $10.23.
As of Sep 22, 2023, there are 364.33M shares of BHC outstanding. The market value of BHC is $2.99B. In the last 24 hours, 4.34M BHC shares were traded.
You will need a brokerage account in order to access the NYSE market and buy BHC stock.
In our opinion, eToro is the best stock brokerage. Here's why:
Get $10 towards your stock purchase by opening an account with eToro now.Open eToro Account
Now that you've selected the best brokerage, it's time to fill out some personal information so you can buy BHC today.
Now that you have opened your account on a mobile trading app, you need to deposit funds:
Check out the walkthrough below for more details transferring funds into your new investment account.
After you have figured out the best place to buy Bausch Health Companies stock, it's critical to analyze their stock before you buy, so you truly understand the risk as well as the upside.
WallStreetZen was designed to help part-time investors perform better fundamental analysis.
You can see all of the due diligence checks on BHC's stock page.
Analysts use many financial metrics, analyses, models, and charts to gauge BHC's fair value.
You can do additional valuation analysis on BHC's stock here.
Out of 2 Wall Street analysts who monitor BHC, the consensus analyst rating on BHC is a Buy
Please note that analyst ratings are not recommendations, nor are they investment advice.
David Steinberg, a top 12% analyst from Jefferies upgrades BHC to a strong buy rating and raises their BHC price target from $9.00 to $16.00, on Sep 20, 2023.
Jefferies's David Steinberg upgraded their rating on Bausch Health Companies (NYSE: BHC) from Hold to Strong Buy on 2023/09/20. The analyst also raised their price target by 77.8% from $9 to $16.
Steinberg suggested Bausch Health "may have some legal victories in the Xifaxan litigation* with updates in Q4 2023 and Q1 2024."
Once all the legal issues are ironed out, "the path to the 80% Bausch & Lomb spin will become more defined," the analyst continued.
Steinberg added that "a positive Xifaxan catalyst increases the probability of the spin and accounts for their price target hike."
* From here: On July 28, 2022, Bausch provided an update on its Xifaxan patent dispute case against Norwich Pharmaceuticals Inc., in which the court ruled that certain Bausch patents were invalid.
From here: On 2023/05/17, Bausch and its gastroenterology business, Salix Pharmaceuticals, announced that the U.S. District Court of Delaware has denied Norwich Pharmaceuticals’ motion to modify the Court’s final judgment that prevents the U.S. FDA from approving Norwich’s ANDA (abbreviated new drug application) for XIFAXAN® (rifaximin) 550 mg before 2029/10/02. As a result of this decision, Norwich’s ANDA cannot be approved until 2029/10/02.
Douglas Miehm, a bottom 6% analyst from RBC Capital maintains BHC with a hold rating and lowers their BHC price target from $9.00 to $8.00, on May 5, 2023.
You can dig deeper into what analysts are saying on the Bausch Health Companies stock forecast page.
Last year, BHC revenue was $8.35B. In the past five year, BHC's revenue has gone up by -0.37% per year. This was slower than the Drug Manufacturers - Specialty & Generic industry average of 24.89%.
Dig into BHC's earnings and revenue performance here.
In the last 12 months, insiders at BHC have sold more shares than they have bought.
Seana Carson, EVP General Counsel of BHC, was the latest BHC insider to sell. They sold $55,351.80 worth of BHC stock on Sep 6, 2023.
Research more about who owns BHC shares here.
No, Bausch Health Companies doesn't provide an income stream by paying out dividends.
One of the primary reasons eToro is our favorite brokerage is because of its social trading community.
Click below to learn what other community members have to say.
You have two main options:
Click the Open button and your broker will place your order.
If you want more info about buying stocks on eToro, watch the helpful video below:
Now that you own some BHC shares, you'll want to stay up-to-date on your investment.
Add BHC to a watchlist to track the latest developments regarding your BHC stock.
To reiterate, here are the 6 steps for buying Bausch Health Companies stock:
If you are looking for a online brokerage, eToro is our favorite venue.Get Started with eToro Today
If you want to get the latest scoop on your investment in Bausch Health Companies, add BHC to your watchlist below.
How much does it cost to buy one Bausch Health Companies share?
Is now a good time to buy Bausch Health Companies stock?
What is the best way to buy Bausch Health Companies stock?